Envoy Medical, Inc. Class A (COCH)

In March 2026, Envoy Medical reported its full-year 2025 financial results, completed enrollment for its Acclaim cochlear implant trial, extinguished over $32 million in debt, and switched auditors. In February 2026, the company regained Nasdaq compliance, secured three new patents, and obtained $30 million in gross proceeds from a public offering. In December 2025, Envoy Medical completed the first set of activations in the Acclaim® cochlear implant study. In September 2025, the company highlighted an expanded global patent portfolio, debt elimination, and progress in the Acclaim® clinical trial. The stock has experienced a significant decline over the past year.

Specific details of demand seasonality for Envoy Medical, Inc.'s products and services are not directly provided. However, the CEO noted consistent interest in their clinical study despite the holiday season, implying potentially consistent demand for their innovative hearing solutions.

Envoy Medical, Inc. is a hearing health company focused on fully implanted hearing solutions, operating in the Healthcare sector and the Surgical & Medical Apparatus industry. Its major products include the Esteem® fully implanted active middle ear implant, commercially available in the U.S. since 2010, and the Acclaim® fully implanted cochlear implant, an investigational device undergoing a U.S.-based pivotal clinical trial.

Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota, United States. The Esteem® FI-AMEI is commercially available in the United States. The Acclaim® cochlear implant is currently undergoing a U.S.-based pivotal clinical trial with investigational sites in locations such as Seal Beach, California, and Tucson, Arizona.

Envoy Medical's brand reputation has been positively influenced by clinical trial progress, FDA Breakthrough Device Designation for the Acclaim® cochlear implant, patent expansion, debt reduction, and transformative financing. These developments aim to bolster its reputation as a leader in fully implanted hearing technology, despite challenges such as a stock price decline and auditor warnings.

Envoy Medical, Inc. has a mixed ownership structure, including institutional, retail, and individual investors. Major institutional shareholders include Vanguard Group Inc. and Weiss Asset Management LP. Billionaire Glen Taylor is a significant individual shareholder. Approximately 13.88% of the company's stock is held by insiders, and retail investors hold approximately 85.24% of the stock.